Suppression of BRCA1 sensitizes cells to proteasome inhibitors.

Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis. Oncotarget (2016) 0.78

BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. Sci Rep (2016) 0.75

Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32

XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell (2001) 18.68

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96

Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet (1996) 12.96

BRCA1 protein products ... Functional motifs... Nat Genet (1996) 11.50

Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma (1997) 11.04

Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28

Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science (2007) 7.61

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev (1993) 7.40

BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev (2000) 7.29

Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59

53BP1, a mediator of the DNA damage checkpoint. Science (2002) 5.00

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev (2000) 3.86

BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol (2009) 3.79

The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell (2006) 3.46

BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature (2011) 3.30

BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res (2006) 3.29

Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell (1998) 3.05

G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell (1991) 2.87

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat (2009) 2.76

p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A (1994) 2.63

Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22

Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res (2007) 2.14

PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res (2009) 2.01

Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov (2013) 1.93

The RB-E2F1 pathway regulates autophagy. Cancer Res (2010) 1.90

Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet (2005) 1.90

Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell (2004) 1.81

BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci U S A (1999) 1.47

BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol (2004) 1.43

NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J Biol Chem (2003) 1.30

IRE1α activation protects mice against acetaminophen-induced hepatotoxicity. J Exp Med (2012) 1.30

Role of ATM and the damage response mediator proteins 53BP1 and MDC1 in the maintenance of G(2)/M checkpoint arrest. Mol Cell Biol (2010) 1.30

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep (2014) 1.25

The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle (2009) 1.23

A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov (2013) 1.17

BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene (1997) 1.15

Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain. J Biol Chem (2000) 1.06

Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer (2012) 1.04

BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation. Oncogene (2012) 1.00

The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation. Mol Cell (2013) 0.95

BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp Cell Res (2006) 0.91